Physician profile
Malcolm R Ing
NPI 1588701080
$5,690.81
in general payments reported to CMS, 2019-2025
25 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $229 · 2021: $193 · 2022: $835 · 2023: $1,223 · 2024: $852 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,075.83 | 2019-2025 | Rocklatan, Argos, Hydrus Microstent |
| Dompe US, INC. | $534.37 | 2022-2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $480.76 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $394.41 | 2019-2023 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $334.55 | 2019-2024 | Cequa |
| Amgen INC. | $330.71 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $307.27 | 2019-2022 | |
| Abbvie INC. | $233.49 | 2022-2025 | |
| Oyster Point Pharma, INC. | $199.42 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $186.77 | 2019-2023 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Allergan, INC. | $183.27 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $166.93 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $155.42 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $154.27 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $143.36 | 2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $128.60 | 2025 | Syfovre |
| Rxsight INC | $119.56 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $113.47 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $98.87 | 2021-2022 | |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.55 | 2019-2020 | |
| Glaukos Corporation | $71.04 | 2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $66.16 | 2020-2021 | |
| Biotissue Holdings INC. | $39.75 | 2025 | |
| Staar Surgical Company | $16.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Ing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.